Theracryf Plc · LSE:TCF
Theracryf — Evgen Pharma — Merger or Acquisition (April 2024)
12 slides from Theracryf's merger presentation, April 2024
Slide 1: Corporate Presentation
Corporate Presentation April 2024 AIM: EVG.L NOMAD: Cavendish Dr Huw Jones, CEO IR: Instinctif, CAG Toni Haenninen, CFO Dr Helen Kuhlman, CBO
Slide 2: Important notice and disclaimer
THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA
Slide 3: Mission
MISSION To build a drug development powerhouse in profitable segments within oncology and behavioural brain disorders
Slide 4: Explore Early Partnering Opportunities
Explore Early Partnering Opportunities External Conserve Validation of Cash Technology Biotech Imperatives 2024 Generate General Pre-clinical Clinical Data Data Seek Attractive M&A Opportunities
Slide 5: Proposed Acquisition of Chronos Therapeutics Ltd
Proposed Acquisition of Chronos Therapeutics Ltd in an all-share transaction* Neuropsychiatry portfolio, attractive targets, resurgent area for big pharma Accompanying Capital raise Renaming of the combined company *Approx 10% of upfront consideration in cash
Slide 6: Neuroscience deal activity in big pharma
HEALTH AND SCIENCE AbbVie pads neuroscience portfolio with As J&J outlines bullish pipeline Karuna Therapeutics surges 47% $8.7B deal to acquire Cerevel goals, neuroscience pipeline after Bristol Myers Squibb Annalee Armstrong takes a starring role announces $14 billion deal By Max Bayer Published D
Slide 7: Evgen and Chronos company profiles
Clinical stage Late Pre-clinical stage • Developing a new class of pharmaceuticals - based on • Spin out of Oxford University, lifetime raise £15.4m highly biologically active “sulforaphane” - applications in multiple therapeutic areas based on a network of targets • 2016 acquisition of 3 NCE assets
Slide 8: Transaction Details
Transaction Details Low upfront, de-risked and back-weighted • Acquisition of entire issued share capital of Chronos Therapeutics o Single share class, no warrants, no debt, on a cash and debt free basis • £1m in Evgen shares upfront to Chronos shareholders* o Includes Vulpes, Odey, Oxford Universit
Slide 9: Combined Group Pipeline
Combined Group Pipeline SFX-01: Breast Cancer SFX-01: Neurodevelopmental Disorders SFX-01: Glioblastoma* SFX-01: Rhabdomyosarcoma NCE: Ox1 in Addiction NCE: Ox1 in Anxiety NCE: DAT in Fatigue / Narcolepsy* * Orphan Conditions
Slide 10: Rationale for Combination
Rationale for Combination • More than triples the size of the Evgen portfolio • Capitalising on renewed interest and deal activity in Neuroscience • Chronos neuropsychiatry assets are complementary to Evgen’s neurodevelopmental disorders and brain cancer asset • Evgen has the expertise to develop an
Slide 11: Evgen Management and Board
Evgen Management and Board Dr Huw Jones Toni Haenninen Dr Sue Foden CEO CFO Chair Over 30 years’ experience of leadership Over 20 years’ experience of financial Executive Chair of QBiotics Group Ltd in public and private R&D-based leadership in public and private and an NED on the board of Laverock
Slide 12: Thank You
An exciting opportunity to build a drug development powerhouse in oncology and behavioural brain disorders Thank You Evgen Pharma Plc enquiries@evgen.com www.evgen.com